=> b reg FILE 'REGISTRY' ENTERED AT 15:55:23 ON 08 NOV 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 NOV 2006 HIGHEST RN 912617-52-8 DICTIONARY FILE UPDATES: 7 NOV 2006 HIGHEST RN 912617-52-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta 17 L5 ST

NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE L7 64 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 366133 ITERATIONS SEARCH TIME: 00.00.20

64 ANSWERS

=> d que sta l11

NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 14


STEREO ATTRIBUTES: NONE

L7

64 SEA FILE=REGISTRY SSS FUL L5

L8

STR



VAR G1=AK/CY NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L11

0 SEA FILE=REGISTRY SUB=L7 SSS FUL L8

100.0% PROCESSED

64 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

=> b hcap FILE 'HCAPLUS' ENTERED AT 15:55:41 ON 08 NOV 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Nov 2006 VOL 145 ISS 20 FILE LAST UPDATED: 7 Nov 2006 (20061107/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr retable 121 tot

L21 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

```
2004:333687 HCAPLUS Full-text
AN
     140:339637
DN
ΤI
     Preparation of peptidomimetic \mu-opioid receptor ligands
IN
     Harrison, Bryce; Gierasch, Tiffany Malinky;
     Verdine, Gregory L.; Shi, Zhangjie
PA
     President and Fellows of Harvard College, USA
SO
     PCT Int. Appl., 128 pp.
     CODEN: PIXXD2
DT
     Patent
   . English
LΑ
FAN.CNT 1
     PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                   DATE
                         _ _ _ _
                                -----
                                             ------
                                                                    -----
PΙ
     WO2004033414
                          A1
                                20040422
                                            2003WO-US32280
                                                                   20031010
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU2003279953
                          Α1
                                20040504
                                          2003AU-0279953
                                                                   20031010
     US2004254225
                          A1
                                20041216
                                            2003US-0683756
                                                                   20031010
PRAI 2002US-417925P
                          Ρ
                                20021011
     2003US-443428P
                          Ρ
                                20030129
     2003WO-US32280
                          W
                                20031010
OS
     MARPAT 140:339637
AB
     The invention relates to peptidomimetic compds. derived from aralkyl-substituted
     aminodihydroxyalk(en)oic acids which are modulators of the \mu-opioid receptor (MOR) and
     thus have therapeutic applications. The claims include compds. of general formula
     R52NCHR1CH(OH)CH2CHRCHRCH(OH)CHR2CO-X-CHR3R4 [R2 is H2 or a bond; X is N, O or S; R1-R3
     are (un) substituted (hetero) arylalkyl; R4 is H, CONR72 (R7 is H, alkyl, acyl or a
     protecting group), CONHR7, CH2OH, CH(OH)CH:CH2 or CONHCHR10CO2H (R10 is an amino acid
     side chain); R5 is H, alk(en)yl, (hetero)aryl, acyl, a protecting group or COCHR10CO2H]
     or their pharmaceutically-acceptable salts. Thus, stereoisomeric H2NCH(CH2C6H4OH-
     p)CH(OH)CH2CH:CHCH(OH)CH(CH2Ph)CONHCH(CH2Ph)CONH2 (2) were prepared and assayed for
     binding affinity for MOR [8.8 \pm 0.7 nM for (S,S,S,R)-2, vs. 1.2 \pm 0.1 nM for
     endomorphin 2].
     479495-67-5P 479495-68-6P 479495-69-7P
     479495-70-0P 479495-71-1P 479495-72-2P
     479495-73-3P 479495-74-4P 479495-75-5P
     479495-76-6P 479495-77-7P 479495-78-8P
     479495-79-9P 479495-80-2P 479495-81-3P
     479495-83-5P 479495-84-6P 479495-85-7P
     479495-86-8P 479496-03-2P 479496-04-3P
     479496-05-4P 479496-06-5P 479496-11-2P
     479496-12-3P 479496-13-4P 479496-14-5P
     479496-15-6P 479496-16-7P 479496-17-8P
     479496-18-9P 479496-19-0P 503186-38-7P
     503186-39-8P 503186-40-1P 503186-41-2P
     503186-42-3P 503186-43-4P 503186-44-5P
     503186-45-6P 503186-46-7P 503186-47-8P
     503186-48-9P 507276-41-7P 507276-43-9P
     507276-45-1P 507276-47-3P 507276-49-5P
     507276-51-9P 507276-53-1P 507276-55-3P
    507276-57-5P 507276-59-7P 507276-61-1P
     507276-63-3P 507276-65-5P 507276-67-7P
    507276-69-9P 507276-71-3P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of peptidomimetic \mu-opioid receptor ligands)
IT
     680187-48-8DP, resin-bound 680187-49-9DP, resin-bound
```

680187-50-2DP, resin-bound 680187-51-3DP, resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of peptidomimetic μ -opioid receptor ligands) 479495-67-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptidomimetic μ -opioid receptor ligands)

RN 479495-67-5 HCAPLUS

CN Benzenepropanamide, α -[(1R,2E,5R,6R)-6-amino-1,5-dihydroxy-7-(4hydroxyphenyl)-2-heptenyl]-N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-, (αS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RETABLE

TΨ

Referenced Author (RAU)	Year (RPY)		PG (RPG)	Referenced Work (RWK)	Referenced File
	+=====	+=====	+======	+======================================	+=======
Gierasch	2000	2	3999	ORGANIC LETTERS	HCAPLUS
Harrison, B	2002	124	13352	J AM CHEM SOC	HCAPLUS
Harrison, B	2003	46	677	J MED CHEM	HCAPLUS
Sepracor Inc	1999	Ì	İ	WO9965932 A	HCAPLUS

- L21 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
- 2003:110339 HCAPLUS Full-text ΑN
- DN 138:297095
- Unpredictable Stereochemical Preferences for Mu Opioid Receptor Activity TI in an Exhaustively Stereodiversified Library of 1,4-Enediols
- Shi, Zhangjie; Harrison, Bryce A.; Verdine, AU Gregory L.
- CS Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA
- so Organic Letters (2003), 5(5), 633-636 CODEN: ORLEF7; ISSN: 1523-7060
- PB American Chemical Society
- DT Journal
- LΑ English
- os CASREACT 138:297095
- GI

Using olefin cross-metathesis, the authors synthesized a novel stereodiversified library of I containing a trans-1,4-enediol. Screening this library for mu opioid receptor (MOR) affinity identified multiple high-affinity ligands and revealed that the stereochem. configuration varied widely among those ligands having the highest affinity. It was not possible to predict the configurations of the most active I stereoisomers on the basis of the configuration of endomorphin-2, a known MOR peptide ligand, validating the diversity-based approach to ligand discovery.

IT 507276-41-7P 507276-43-9P 507276-45-1P 507276-47-3P 507276-49-5P 507276-51-9P 507276-53-1P 507276-55-3P 507276-57-5P 507276-59-7P 507276-61-1P 507276-63-3P 507276-65-5P 507276-67-7P 507276-69-9P 507276-71-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (unpredictable stereochem. preferences for mu opioid receptor activity in an exhaustively stereodiversified library of enediols in relation to partial agonist activity)

IT 507276-41-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (unpredictable stereochem. preferences for mu opioid receptor activity in an exhaustively stereodiversified library of enediols in relation to partial agonist activity)

RN 507276-41-7 HCAPLUS

CN Benzenepropanamide, α-[(1R,2E,4R,6R)-6-amino-1,4-dihydroxy-7-(4hydroxyphenyl)-2-heptenyl]-N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Blackwell, H	2000	122	58	J Am Chem Soc	HCAPLUS
Bylund, D	1990	i	1	Methods in Neurotran	1
Dooley, C	1999	51	379	Biopolymers	HCAPLUS
Furstner, A	2000	39	3012	Angew Chem, Int Ed	HCAPLUS
Gierasch, T	İ	ĺ	j	Manuscript submitted	
Gierasch, T	2000	2	3999	Org Lett	HCAPLUS
Gordon, E	1988	31	2199	J Med Chem	HCAPLUS
Harrison, B	2002	124	13352	J Am Chem Soc	HCAPLUS
Harrison, B	2001	3	2157	Org Lett	HCAPLUS
Law, P	1999	51	440	Biopolymers	HCAPLUS
Michielin, O	2002	124	11131	J Am Chem Soc	HCAPLUS
Nicolaou, K	2000	122	9954	J Am Chem Soc	HCAPLUS
Pasternak, G	2001	68	2213	Life Sci	HCAPLUS
Pasternak, G	1990	6	1	Mod Methods Pharmaco	HCAPLUS
Pelish, H	2001	123	6740	J Am Chem Soc	HCAPLUS
Scholl, M	1999	1	953	Org Lett	HCAPLUS
Schreiber, S	2000	287	1964	Science	HCAPLUS
Standifer, K	1997	9	237	Cell Signalling	HCAPLUS
Stockwell, B	2000	1	116	Nat Rev Genet	HCAPLUS
Tan, D	1998	120	8565	J Am Chem Soc	HCAPLUS
Zadina, J	1999	897	136	Ann N Y Acad Sci	HCAPLUS
Zadina, J	1997	386	499	Nature	HCAPLUS

ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN L21 AN 2003:72698 HCAPLUS Full-text DN 138:271935 ΤI 2,6-Dimethyltyrosine Analogues of a Stereodiversified Liqand Library: Highly Potent, Selective, Non-Peptidic μ Opioid Receptor Agonists Harrison, Bryce A.; Pasternak, Gavril W.; Verdine, Gregory ΑU L. CS Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA Journal of Medicinal Chemistry (2003), 46(5), 677-680 SO CODEN: JMCMAR; ISSN: 0022-2623 PB American Chemical Society DTJournal LΑ English OS CASREACT 138:271935

GI

AB

analogs I (X = NH, R = CONH2; X = NH, R = H; X = NH, R = CH2OH; X = O, R = CONH2; X = O, R = H; X = O, R = CH2OH) towards μ -opioid receptor. For I (X = NH, R = CONH2; X = NH, R = H), five stereoisomers of each compound were synthesized and their bioactivity evaluated, discovering certain stereoisomers with unexpected potency, selectivity, and efficacy. 503186-38-7P 503186-39-8P 503186-40-1P TT 503186-41-2P 503186-42-3P 503186-43-4P 503186-44-5P 503186-45-6P 503186-46-7P 503186-47-8P 503186-48-9P RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (asym. preparation of enediol-based nonpeptidic analogs of dimethyltyrosine and their evaluation as μ -opioid receptor agonists) ΙT 503186-38-7P RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (asym. preparation of enediol-based nonpeptidic analogs of dimethyltyrosine and their evaluation as μ -opioid receptor agonists) RN 503186-38-7 HCAPLUS Benzenepropanamide, α -[(1S,2E,5S,6S)-6-amino-1,5-dihydroxy-7-(4hydroxy-2,6-dimethylphenyl)-2-heptenyl]-N-[(1S)-2-amino-2-oxo-1-(phenylmethyl) ethyl] -, (\alpha R) - (9CI) (CA INDEX NAME)

The authors report the synthesis and bioactivity of enediol-based 2,6-dimethyltyrosine

Absolute stereochemistry.

Double bond geometry as shown.

-	_		_	_	_
R	н:	T'A	۱н		ıн:

Referenced Author	Year	Or	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====	+====-	+=====	+======================================	+========
Adamson, J	1991	56	3447	J Org Chem	HCAPLUS
Balboni, G	2002	45	713	J Med Chem	HCAPLUS
Blackwell, H	2000	122	58	J Am Chem Soc	HCAPLUS
Chandrakumar, N	1992	35	223	J Med Chem	HCAPLUS
Chandrakumar, N	1992	35	2928	J Med Chem	HCAPLUS
Furstner, A	2000	39	3012	Angew Chem, Int Ed	HCAPLUS
Gierasch, T	2000	2	3999	Org Lett	HCAPLUS
Hansen, D	1992	35	684	J Med Chem	HCAPLUS
Harrison, B	2002	124	13352	J Am Chem Soc	HCAPLUS
Harrison, B	2001	3	2157	Org Lett	HCAPLUS
Michielin, O	2002	124	11131	J Am Chem Soc	HCAPLUS
Nicolaou, K	2000	122	9954	J Am Chem Soc	HCAPLUS
Pasternak, G	1990	6	1	Mod Methods Pharmaco	HCAPLUS
Pelish, H	2001	123	6740	J Am Chem Soc	HCAPLUS
Pitzele, B	1994	37	888	J Med Chem	HCAPLUS
Salvadori, S	1999	42	5010	J Med Chem	HCAPLUS
Schiller, P	2000	35	895	Eur J Med Chem	HCAPLUS
Schiller, P	1999	42	3520	J Med Chem	HCAPLUS
Scholl, M	1999	1	953	Org Lett	HCAPLUS
Schreiber, S	2000	287	1964	Science	HCAPLUS
Stockwell, B	2000	1	116	Nat Rev Genet	HCAPLUS
Tan, D	1998	120	8565	J Am Chem Soc	HCAPLUS
Zadina, J	1999	897	136	Ann N Y Acad Sci	HCAPLUS
Zadina, J	1997	386	499	Nature	HCAPLUS

L21 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:808520 HCAPLUS Full-text

DN 138:55660

ΤI High-Affinity Mu Opioid Receptor Ligands Discovered by the Screening of an Exhaustively Stereodiversified Library of 1,5-Enediols

ΑU Harrison, Bryce A.; Gierasch, Tiffany Malinky; Neilan, Claire; Pasternak, Gavril W.; Verdine, Gregory L.

Department of Chemistry and Chemical Biology, Harvard CS

University, Cambridge, MA, 02138, USA Journal of the American Chemical Society (2002), 124(45), 13352-13353 SO CODEN: JACSAT; ISSN: 0002-7863

PΒ American Chemical Society

DTJournal

LΑ English

os CASREACT 138:55660

GI

AB A stereodiversified library of all 16 stereoisomers of 1,5-enediol I was synthesized, and these compds. were screened for mu opioid receptor (MOR) binding. The stereochem. configuration of I strongly impacted the binding affinity, and (S,S,S,R)-I exhibited a Ki of 8.8 nM for MOR, comparable to that of endomorphin-2 (Ki = 1.2 nM). Moreover, compds. I exhibited 5-86-fold selectivity for MOR over delta opioid receptor (DOR) and 16-150-fold selectivity for MOR over kappa opioid receptor (KOR). Addnl., analogs of I were synthesized which showed that the trans configuration of the olefin was important for receptor binding but modifications of the C-terminal amino acid were well tolerated. Of these analogs, tetraols II are noteworthy because they retain only one of the amide bonds present in endomorphin-2, but bind MOR with an affinity of 10 nM and 110- and 600-fold selectivity for MOR over DOR and KOR. These results demonstrate the utility of stereochem. diversity in the discovery of bioactive small mols.

479495-67-5P 479495-68-6P 479495-69-7P 479495-70-0P 479495-71-1P 479495-72-2P 479495-76-6P 479495-75-5P 479495-76-6P 479495-77-7P 479495-78-8P 479495-79-9P 479495-80-2P 479495-81-3P 479495-82-4P 479495-83-5P 479495-84-6P 479495-85-7P 479495-86-8P 479496-03-2P 479496-04-3P 479496-05-4P 479496-13-4P 479496-11-2P 479496-15-6P 479496-16-7P 479496-17-8P 479496-18-9P 479496-19-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of amino(dihydroxy)nonenamides and derivs. as nonpeptidic high-affinity μ -opioid receptor ligands)

IT 479495-67-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of amino(dihydroxy)nonenamides and derivs. as nonpeptidic high-affinity μ -opioid receptor ligands)

RN 479495-67-5 HCAPLUS

CN Benzenepropanamide, α-[(1R,2E,5R,6R)-6-amino-1,5-dihydroxy-7-(4-hydroxyphenyl)-2-heptenyl]-N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
=======================================	+=====	+====- ·	+=====	+======================================	+=======
Annis, D	1998	37	1907	Angew Chem, Int Ed	HCAPLUS
Blackwell, H	2000	122	58	J Am Chem Soc	HCAPLUS
Bunin, B	1997	21	125	New J Chem	HCAPLUS
Cusack, N	1976	32	2157	Tetrahedron	HCAPLUS
Dooley, C	1999	51	379	Biopolymers	HCAPLUS
Furstner, A	2000	39	3012	Angew Chem, Int Ed	HCAPLUS
Gierasch, T	2000	2	3999	Org Lett	HCAPLUS
Harrison, B	2001	3	2157	Org Lett	HCAPLUS
Hruby, V	1999	51	391	Biopolymers	HCAPLUS
Kingsbury, C	1999	3	497	Curr Org Chem	HCAPLUS
Lacombe, P	1998	39	6785	Tetrahedron Lett	HCAPLUS
Mitchison, T	1994	1	3	Chem Biol	HCAPLUS
Nicolaou, K	2000	122	9954	J Am Chem Soc	HCAPLUS

```
Pasternak, G
                                 2213
                     |2001 |68
                                       |Life Sci
                                                            HCAPLUS
                     |1990 |6
Pasternak, G
                                        |Mod Methods Pharmaco|HCAPLUS
                                 11
Paterson, I
                     1999
                                        J Chem Soc, Perkins | HCAPLUS
                                 1003
Paterson, I
                     1992 | 33
                                        Tetrahedron Lett
                                 797
                                                            HCAPLUS
Scholl, M
                     |1999 |1
                                 953
                                        Org Lett
                                                            HCAPLUS
Schreiber, S
                     1998 | 6
                                 1127
                                        |Bioorq Med Chem
                                                           HCAPLUS
Schreiber, S
                     2000 287
                                 1964
                                        Science
                                                            HCAPLUS
                     1997 | 9
Standifer, K
                                 237
                                        |Cell Signalling
                                                           HCAPLUS
Stockwell, B
                     2000 1
                                 1116
                                        Nat Rev Genet
                                                            HCAPLUS
Tan, D
                                 8565 J Am Chem Soc
                     1998 | 120
                                                            | HCAPLUS
Zadina, J
                     |1999 |897
                                 136
                                        Ann N Y Acad Sci
                                                            | HCAPLUS
Zadina, J
                     |1997 |386 |499
                                       Nature
                                                            HCAPLUS
```

```
=> b uspatall
```

FILE 'USPATFULL' ENTERED AT 15:56:17 ON 08 NOV 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:56:17 ON 08 NOV 2006 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 122 tot

```
L22 ANSWER 1 OF 1 USPATFULL on STN
      2004:321570 USPATFULL Full-text
AN
      Mu opioid receptor ligands: methods of use and synthesis
ΤI
      Harrison, Bryce A., Hamilton, NJ, UNITED STATES
IN
      Gierasch, Tiffany M., Bryn Mawr, PA, UNITED STATES
      Verdine, Gregory L., Newton, MA, UNITED STATES
      Shi, Zhangjie, Chicago, IL, UNITED STATES
ΡI
      US2004254225
                     A1
                              20041216
      2003US-0683756
ΑI
                        A1
                              20031010 (10)
PRAI
      2002US-417925P
                        20021011 (60)
      2003US-443428P
                        20030129 (60)
DT
      Utility
FS
      APPLICATION
LREP
      EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205
CLMN
      Number of Claims: 38
ECL
      Exemplary Claim: 1
      4 Drawing Page(s)
LN.CNT 3735
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease or disease symptoms in a subject (e.g., mammal, human, dog, cat, horse). The compounds are useful as modulators of the mu opioid receptor (MOR) through their binding affinity with that receptor.

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
    479495-67-5P 479495-68-6P 479495-69-7P
      479495-70-0P 479495-71-1P 479495-72-2P
      479495-73-3P 479495-74-4P 479495-75-5P
      479495-76-6P 479495-77-7P 479495-78-8P
      479495-79-9P 479495-80-2P 479495-81-3P
      479495-83-5P 479495-84-6P 479495-85-7P
      479495-86-8P 479496-03-2P 479496-04-3P
     479496-05-4P 479496-06-5P 479496-11-2P
     479496-12-3P 479496-13-4P 479496-14-5P
     479496-15-6P 479496-16-7P 479496-17-8P
     479496-18-9P 479496-19-0P 503186-38-7P
     503186-39-8P 503186-40-1P 503186-41-2P
     503186-42-3P 503186-43-4P 503186-44-5P
     503186-45-6P 503186-46-7P 503186-47-8P
     503186-48-9P 507276-41-7P 507276-43-9P
     507276-45-1P 507276-47-3P 507276-49-5P
```

507276-51-9P 507276-53-1P 507276-55-3P 507276-57-5P 507276-59-7P 507276-61-1P 507276-63-3P 507276-65-5P 507276-67-7P 507276-69-9P 507276-71-3P (preparation of peptidomimetic µ-opioid receptor ligands) IT 680187-48-8DP, resin-bound 680187-49-9DP, resin-bound 680187-50-2DP, resin-bound 680187-51-3DP, resin-bound (preparation of peptidomimetic μ -opioid receptor ligands) 479495-67-5P IT (preparation of peptidomimetic μ-opioid receptor ligands) RN 479495-67-5 USPATFULL CN Benzenepropanamide, α -[(1R, 2E, 5R, 6R)-6-amino-1, 5-dihydroxy-7-(4hydroxyphenyl) -2-heptenyl] -N-[(1S) -2-amino-2-oxo-1-(phenylmethyl) ethyl] -, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

=> d his

L3

(FILE 'HOME' ENTERED AT 15:33:20 ON 08 NOV 2006)

FILE 'HCAPLUS' ENTERED AT 15:33:28 ON 08 NOV 2006 1 US20040254225/PN OR (US2003-683756 OR US2002-417925# OR US2003-Ll

FILE 'REGISTRY' ENTERED AT 15:34:31 ON 08 NOV 2006

FILE 'HCAPLUS' ENTERED AT 15:34:41 ON 08 NOV 2006 L2 TRA L1 1- RN : 155 TERMS

FILE 'REGISTRY' ENTERED AT 15:34:41 ON 08 NOV 2006 155 SEA L2

L4STR

STR L4 L5

L6 1 L5 L7

64 L5 FULL DEL VAL756B/Q

SAV TEM L7 VAL756B/A

L8STR L4

L9 0 L8 SAM SUB=L7

63 L7 AND L3 L10

L11 0 L8 FULL SUB=L7

FILE 'HCAPLUS' ENTERED AT 15:52:29 ON 08 NOV 2006

L12 4 L7

E HARRISON B/AU

L13 50 E3-4

E HARRISON BRYCE/AU

L14 8 E3-5

E GIERASCH T/AU

L15 6 E4-5

E VERDINE G/AU

L16 195 E4-7

E SHI Z/AU

L17 395 E3-24